SENTARA COMMUNITY PLAN
(MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: **The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request**. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Antiparkinson Agents

Drug Requested: (Select applicable drug below)

❑ **Crexont®** (carbidopa-levodopa ER capsules)	❑ **Ongentys®** (opicapone capsules)
❑ **Inbrija™** (levodopa inhalation powder)	❑ **tolcapone** (Tasmar) **tablets**
❑ **Lodosyn®** (carbidopa tablets)	❑ **Rytary®**(carbidopa-levodopa ER capsules)
❑ **Neupro®** (rotigotine transdermal system)	❑ **Xadago™** (safinamide tablets)
❑ **Nourianz™** (istradefylline tablets)	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy**: _____

Diagnosis: _____ **ICD Code, if applicable:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosage:

- **Crexont®:** Oral: Initial: Carbidopa 35 mg/levodopa 140 mg twice daily for 3 days; may increase dose gradually up to a maximum of carbidopa 525 mg/levodopa 2.1 g per day, in up to 4 divided doses, Maximum quantity limit: 6 capsules per day (all strengths).

(Continued on next page)

- **Inbrija™:** Oral inhalation: 84 mg up to 5 times daily as needed when symptoms of an OFF period return up to a maximum of 84 mg/dose and 420 mg/day. Maximum quantity limit: 10 capsules per day.
- **Lodosyn® :** Oral: Initial: 25 mg daily with first daily dose of carbidopa/levodopa; if necessary, 12.5 to 25 mg may be given with each subsequent dose of carbidopa/levodopa. Maximum quantity limit: 8 tablets per day.
- **Neupro®:** *Early-stage Parkinson Disease:* Transdermal: Initial: Apply 2 mg/24 hours patch once daily; may increase daily dose by 2 mg/24 hours weekly based on clinical response and tolerability. Maximum: 6 mg/24 hours.

  Advanced-stage Parkinson Disease: Transdermal: Initial: Apply 4 mg/24 hours patch once daily; may increase daily dose by 2 mg/24 hours weekly based on clinical response and tolerability. Maximum: 8 mg/24 hours. Maximum quantity limit: 30 patches/30 days (all strengths).

  Restless legs syndrome : Initial: Transdermal: Apply 1 mg/24 hours patch once daily; may increase daily dose by 1 mg/24 hours weekly, based on clinical response and tolerability to a maximum of 3 mg/24 hours. Maximum quantity limit: 30 patches/30 days (all strengths).
- **Nourianz™:** Oral: 20 mg once daily; may further increase dose based on response and tolerability to a maximum dose of 40 mg once daily. Maximum quantity limit: 1 tablet per day (both strengths).
- **Ongentys®:** Oral: 50 mg once daily at bedtime. Maximum quantity limit: 1 capsule per day (both strengths).
- **tolcapone (Tasmar):** Oral: Initial: 100 mg 3 times daily always as an adjunct to levodopa/carbidopa; may increase as tolerated to 200 mg 3 times daily. Maximum quantity limit: 6 tablets per day.
- **Rytary®:** Oral: Initial: Carbidopa 23.75 mg/levodopa 95 mg 3 times daily for 3 days; on day 4, may increase to carbidopa 36.25 mg/levodopa 145 mg 3 times daily. Maximum quantity limit: 10 capsules per day (all strengths).
- **Xadago™:** Oral: 50 mg once daily (in combination with carbidopa/levodopa); after 2 weeks may increase to 100 mg once daily (in combination with carbidopa/levodopa) based on response and tolerability. Maximum quantity limit: 1 tablet per day (both strengths).

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- ❑ Member must be 18 years of age or older
- ❑ Medication must be prescribed by, or in consultation with a neurologist
- ❑ Member must have a confirmed diagnosis of Parkinson's disease in an individual who is having intermittent OFF episodes while on continuous carbidopa/levodopa therapy and **ALL** the following criteria has been met **(must submit chart notes)**:
  - ❑ Provider has made adjustments to member's carbidopa/levodopa's dose in order to manage symptoms without success
  - ❑ Member is receiving concurrent therapy with carbidopa/levodopa **within the past 30 days** **AND** the requested medication will be used in combination with continuous carbidopa/levodopa treatment

(Continued on next page)

- ❑ Member is currently not taking or has not recently (within 2 weeks) taken a nonselective MAO inhibitor such as Nardil® (phenelzine), Parnate® (tranylcypromine), or Marplan® (isocarboxazid)

❑ Member must meet **ALL** criteria for requested drug below if prescribed for treatment of Parkinson's disease

❑ **For Crexont & Rytary®,** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of trial and failure of **BOTH** of the following:
  - ❑ Combination therapy of carbidopa/levodopa IR with carbidopa/levodopa extended-release
  - ❑ Member must have documentation of trial and failure of **ONE** of the following:
    - ❑ Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER
    - ❑ Monoamine oxidase type B inhibitors: rasagiline
    - ❑ COMT inhibitor: generic entacapone

❑ **For Inbrija® or Nourianz®,** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of trial and failure of **TWO (2)** of the following:
  - ❑ Monoamine oxidase type B inhibitors: rasagiline
  - ❑ Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER
  - ❑ COMT inhibitor: generic entacapone, Ongentys® (*requires prior authorization), tolcapone (*requires prior authorization)
- ❑ **For Inbrija requests**: Member does **NOT** have a history of asthma, COPD, or other chronic underlying lung disease

❑ **For Lodosyn®,** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member is currently receiving carbidopa/levodopa therapy and Lodosyn (carbidopa) is being used in combination to levodopa therapy to reduce the side effects (i.e., nausea) associated and to enhance the effectiveness of levodopa therapy.

(Continued on next page)

❑ **For Neupro®,** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of **ONE** of the following diagnoses:
  - ❑ Parkinsons Disease
  - ❑ Moderate to severe restless leg syndrome
- ❑ **For Parkinsons Disease:**
  - ❑ Member must meet **ONE** of the following:
    - ❑ Member must meet all initial criteria listed above and have documentation of trial and failure or intolerance to **BOTH** of the following oral dopamine agonists:
      - ❑ pramipexole immediate release tablets
      - ❑ ropinirole extended-release release tablets
    - ❑ Prescriber indicates the patient is unable to swallow or take medications orally
- ❑ **For Restless Legs Syndrome:**
  - ❑ Member must meet **ONE** of the following:
    - ❑ Member must have documentation of trial and failure or intolerance to **TWO** of the following oral dopamine therapies:
      - ❑ pramipexole immediate release tablets
      - ❑ ropinirole extended-release release tablets
    - ❑ Member must have documentation of gabapentin or pregabalin for those with an intolerance to dopamine agonists
    - ❑ Prescriber indicates the member is unable to swallow or take medications orally

❑ **For Ongentys®.** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of trial and failure of a COMT inhibitor: generic entacapone
- ❑ Member does **NOT** have a history of pheochromocytoma, paraganglioma, or other catecholamine-secreting neoplasms

❑ **For tolcapone (Tasmar).** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of trial and failure of **ALL** the following:
  - ❑ COMT inhibitors: generic entacapone and Ongentys® (opicapone) (*requires prior authorization)
  - ❑ Dopamine agonist: ropinirole/ropinirole ER, pramipexole/pramipexole ER
  - ❑ Monoamine oxidase type B inhibitors: rasagiline

(Continued on next page)

- ❑ Provider attests to monitoring of liver failure/hepatic dysfunction and should discontinue tolcapone if ALT/AST levels exceed 2 times the upper limit of normal

❑ **For Xadago®,** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must have documentation of trial and failure or intolerance to **BOTH** of the following monoamine oxidase inhibitors:
  - ❑ selegiline
  - ❑ rasagiline
- ❑ Member does **NOT** have severe hepatic impairment (Chld-Pugh C)

❑ **Reauthorization: 12 months.** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ❑ Member must continue to meet all applicable initial authorization criteria
- ❑ Member has a documented positive clinical response to treatment (defined as: improvement and stabilization of "off episodes" associated with Parkinson's disease)
- ❑ Requested medication is used in combination with carbidopa/levodopa **(verified by pharmacy paid claims)**
- ❑ Member must be absent of unacceptable toxicity from therapy

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****

***Approved by Pharmacy and Therapeutics Committee**: ~~9/20/2019; 2/20/2020;~~ **1/23/2025**
REVISED/UPDATED/REFORMATTED: ~~10/8/2019; 6/11/2020; 4/1/2021; **6/14/2021;**~~ **2/18/2025**